ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.